benign prostatic hyperplasia
Researchers from NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered a new gene fusion that is highly expressed in a subset of prostate cancers. The results may lead to more accurate prostate cancer testing and new targets for potential treatments.
Use of the medication tamsulosin to treat male urination difficulties within two weeks of cataract surgery is associated with an increased risk of serious postoperative ophthalmic adverse events such as retinal detachment or lost lens, according to a study in the May 20 issue of JAMA.
LINTHICUM, MD, April 26, 2009-Tadalafil may improve lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH). Researchers from Nashville, Dallas, San Antonia and Indianapolis will present these findings during the 104th Annual Scientific Meeting of the American Urological Association (AUA).
The PSA test, commonly used as a screening tool for detecting prostate cancer, is now all but useless for predicting prostate cancer risk, according to Stanford University School of Medicine researchers. A study of prostate tissues collected over 20 years - from the time it first became standard to remove prostates in response to high PSA levels to the present - reveals that as a screen, the test now indicates nothing more than the size of the prostate gland. ''The PSA era is over in the United States,'' said Thomas Stamey, MD, professor of urology and lead author of the study published in the October issue of the Journal of Urology. ''Our study raises a very serious question of whether a man should even use the PSA test for prostate cancer screening any more.''
A combination of drugs is significantly more effective than either drug alone for preventing progression of benign prostatic hyperplasia (BPH), especially in men at high risk for disease progression, according to a study appearing in the New England Journal of Medicine tomorrow. The Medical Therapy of Prostatic Symptoms (MTOPS) Trial tested whether finasteride (Proscar), doxazosin (Cardura) or a combination of the drugs could prevent progression of BPH and the need for surgery or other invasive treatments. Treatments were compared to placebo.
